Entero Healthcare Solutions Limited , a leading healthcare supply chain company, has reported robust financial results for the second quarter and half-year ended September 30, 2025, while also announcing strategic acquisitions to bolster its market position.

Financial Highlights

For Q2 FY26, Entero Healthcare reported consolidated revenue from operations of Rs. 15,709.48 crore, marking a significant increase from Rs. 13,006.92 crore in the same quarter last year. The company's profit after tax rose to Rs. 366.00 crore, up from Rs. 260.33 crore in Q2 FY25.

Key financial metrics for H1 FY26 include:

The company's EBITDA margin improved to 3.8% in H1 FY26, compared to 3.0% in H1 FY25.

Strategic Acquisitions

Entero Healthcare announced two significant acquisitions:

1. Bioaide Technologies Private Limited: The company will acquire an 80% stake in Bioaide for Rs. 31.13-36 crore. Bioaide, incorporated in 1996, is engaged in wholesale distribution of medical devices and healthcare products.

2. Anand Chemiceutics Private Limited: Entero has entered into a binding MoU to acquire a 51% stake in Anand Chemiceutics for Rs. 210-230 crore. This acquisition includes the business operations of Anand Chemiceutics and Anand Healthcare Services.

These acquisitions are expected to strengthen Entero's position in the medical devices distribution sector and expand its geographical presence.

Other Key Developments

• Employee Stock Options: The company allotted 2,030 equity shares at Rs. 804 per share under its Employee Stock Option Plan 2023.

• Leadership Change: Mr. Abhitesh Kumar has been elevated to the position of Chief Growth Officer, reflecting the company's focus on accelerating growth.

• IPO Fund Utilization: As of September 30, 2025, Entero has utilized Rs. 930.07 crore out of the Rs. 951.33 crore net proceeds from its IPO, with the remaining funds deployed in fixed deposits and current accounts.

Prabhat Agrawal, Promoter, Managing Director and CEO of Entero Healthcare Solutions, commented, "The quarter reflects continuation of strong growth trajectory and margin expansion. We achieved an EBITDA Margin of 4% in the quarter through focus on gross margin expansion along with improvement in net working capital days."

Entero Healthcare Solutions continues to demonstrate strong financial performance while strategically expanding its market presence through acquisitions in the healthcare distribution sector.

Entero Healthcare Solutions Limited , a leading healthcare supply chain solutions provider, has reported robust financial performance for the second quarter and half-year ended September 30, 2025, while also announcing significant strategic acquisitions to expand its market presence.

Financial Highlights

For Q2 FY26, Entero Healthcare Solutions reported consolidated revenue from operations of Rs. 15,709.48 crore, marking a substantial increase from Rs. 13,006.92 crore in the corresponding quarter of the previous year. The company's profit after tax for the quarter stood at Rs. 366.00 crore, up from Rs. 260.33 crore in Q2 FY25.

The half-yearly results were equally impressive, with consolidated revenue reaching Rs. 29,747.67 crore, compared to Rs. 23,977.28 crore in H1 FY25. The profit after tax for H1 FY26 increased to Rs. 668.32 crore from Rs. 465.63 crore in the same period last year.

Key Financial Metrics

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Q2 FY26 improved to Rs. 777.21 crore, with an EBITDA margin of 4.95%, showing an improvement in operational efficiency.

Strategic Acquisitions

Entero Healthcare Solutions announced two significant acquisitions to strengthen its market position:

1. Bioaide Technologies Private Limited: The company will acquire an 80% stake in Bioaide Technologies, a Delhi-based distributor of medical devices and healthcare products. The acquisition, valued between Rs. 31.13 crore to Rs. 36 crore, is expected to be completed by February 15, 2026.

2. Anand Chemiceutics Private Limited: Entero has entered into a binding Memorandum of Understanding to acquire a 51% stake in Anand Chemiceutics, a Pune-based wholesale distributor of medical devices. The deal, valued between Rs. 210 crore to Rs. 230 crore, is subject to due diligence and is expected to be completed in FY26.

These acquisitions align with Entero's strategy to expand its distribution network and product portfolio in the healthcare sector.

Corporate Updates

The company also announced several corporate updates:

• Allotment of 2,030 equity shares under the Employee Stock Option Plan 2023, increasing the total paid-up equity share capital to Rs. 43,51,09,370.
• Appointment of Mr. Abhitesh Kumar as Chief Growth Officer, elevating him from his previous role as President – Retail Business & New Initiatives.
• Successful utilization of IPO proceeds, with Rs. 930.07 crore deployed out of the total Rs. 951.33 crore raised.

Management Commentary

Prabhat Agrawal, Promoter, Managing Director and CEO of Entero Healthcare Solutions, commented on the results: "The quarter reflects continuation of strong growth trajectory and margin expansion. We achieved an EBITDA Margin of 4% in the quarter through focus on gross margin expansion along with improvement in net working capital days. As we complete the first half of the year, we remain on-track to deliver on our full-year guidance."

Agrawal added, "We are expanding significantly in the MedTech segment through new acquisitions which marked a pivotal step forward- a move that creates meaningful synergies with our existing pharmaceutical distribution and enhances our overall margin profile."

The company's focus on inorganic growth and operational efficiency appears to be yielding positive results, positioning Entero Healthcare Solutions for continued growth in the evolving healthcare distribution landscape.

Investors and stakeholders will be watching closely to see how these strategic moves translate into long-term value creation for the company.